About Arrowhead Research
Overview
Arrowhead Research Corporation is a holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies. By working closely with leading scientists and universities, Arrowhead identifies the latest advances in nanotechnology and matches them with product development opportunities in high-growth markets. The Company is currently focused on the electronics and biotech industries.
Providing strategic management, financing, and operational services to its subsidiaries, Arrowhead takes an active role in their development, keeping the business and technical development teams at the subsidiary companies focused on near term revenue opportunities and capital efficiency.
Arrowhead’s ultimate goal is to realize the value of its subsidiaries by:
An initial public offering of subsidiary stock
A sale of subsidiary to another company
Building Arrowhead’s ownership position to 100% with revenue from subsidiary flowing to Arrowhead’s bottom line.
Arrowhead is currently focused on its two majority-owned subsidiaries, Unidym, Inc. and Calando Pharmaceuticals, Inc. Arrowhead also owns interests in several other development stage nanotechnology companies.
Operating Subsidiaries:
Arrowhead’s two most mature majorityowned subsidiaries are Unidym, Inc. and Calando Pharmaceuticals, Inc.
Unidym’s products are based on electronics-grade carbon nanotubes (CNTs), a class of molecules with multiple unique properties. For instance, some varieties conduct electricity better than copper, they are stronger than steel, and can be synthesized in bulk quantities. Unidym’s products are intended to replace a key material used in touch panels, LCD displays, and thin-film solar cells, which represents a market opportunity that is estimated to be in excess of $2.5B. Unidym is working in partnership with leading display manufacturers and end user customers to qualify its products with commercial shipment targeted in 2009. Arrowhead owns 80% of Unidym.
Calando is a clinical stage nano-enabled drug delivery company. Calando’s siRNA therapeutic, currently undergoing Phase I clincial testing, is the first to be used to deliver siRNA systemically in humans. RNAi (through siRNA) is a potentially revolutionary new way of treating diverse disease classes; however, the lack of a proven method of delivering siRNA in humans has held the new field back. Arrowhead owns 70% of Calando.
Pipeline:
Arrowhead has interest in four additional nanotechnology companies and plans to selectively add to its portfolio in the future.
Agonn Systems, Inc. ( wholly owned) is exploring, the use of nanotechnology-based energy storage devices for electric vehicles and other power grid market applications.
Tego BioSciences Corporation (wholly owned) has licensed its extensive IP relating to fullerene synthesis and modification for therapeutic purposes in exchange for upfront payments and potential future milestone and royalty payments.
Nanotope, Inc. (22% owned) is a regenerative medicine company developing a suite of products customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial and cartilage.
Leonardo Biosystems, Inc. (6% owned) has a multistage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. It expects to enter into commercial development partnerships in 2010.